Chronic Hepatitis C

References

1. Basit H, Tyagi I, Koirala J. Hepatitis C. [Updated 2022 Nov 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK430897/. Accessed December 4, 2022.

   View in Article

   • Google Scholar
2. • Maasoumy B.
   • Wedemeyer H.
   Natural history of acute and chronic hepatitis C.
   Best Pract Res Clin Gastroenterol. 2012; 26: 401-412
   View in Article

   • Google Scholar
3. • Alter H.J.
   • Holland P.V.
   • Purcell R.H.
   • et al.
   Transmissible agent in non-a, non-b hepatitis.
   The Lancet. 1978; 311: 459-463
   View in Article

   • Google Scholar
4. • Kumar A.
   • Hossain R.A.
   • Yost S.A.
   • et al.
   Structural insights into hepatitis C virus receptor binding and entry.
   Nature. 2021; 598: 521-525
   View in Article

   • Google Scholar
5. • Simmonds P.
   Genetic diversity and evolution of hepatitis C virus - 15 years on.
   J Gen Virol. 2004; 85: 3173-3188
   View in Article

   • Google Scholar
6. • Petruzziello A.
   • Marigliano S.
   • Loquercio G.
   • et al.
   Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes.
   World J Gastroenterol. 2016; 22: 7824-7840
   View in Article

   • Google Scholar
7. • Bukh J.
   The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
   J Hepatol. 2016; 65: S2-S21
   View in Article

   • Google Scholar
8. • Lohmann V.
   Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development.
   Med Microbiol Immunol (Berl). 2019; 208: 3-24
   View in Article

   • Google Scholar
9. • Grakoui A.
   • Wychowski C.
   • Lin C.
   • et al.
   Expression and identification of hepatitis C virus polyprotein cleavage products.
   J Virol. 1993; 67: 1385-1395
   View in Article

   • Google Scholar
10. • Bartenschlager R.
    • Ahlborn-Laake L.
    • Mous J.
    • et al.
    Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions.
    J Virol. 1993; 67: 3835-3844
    View in Article

    • Google Scholar
11. • Tomei L.
    • Failla C.
    • Santolini E.
    • et al.
    NS3 is a serine protease required for processing of hepatitis C virus polyprotein.
    J Virol. 1993; 67: 4017-4026
    View in Article

    • Google Scholar
12. • Ng V.
    • Saab S.
    Effects of a Sustained Virologic Response on Outcomes of Patients With Chronic Hepatitis C.
    Clin Gastroenterol Hepatol. 2011; 9: 923-930
    View in Article

    • Google Scholar
13. • Senior J.R.
    Post-transfusion hepatitis.
    Gastroenterology. 1965; 49: 315-320
    View in Article

    • Google Scholar
14. • Prince A.
    • Grady G.
    • Hazzi C.
    • et al.
    Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-b virus.
    The Lancet. 1974; 304: 241-246
    View in Article

    • Google Scholar
15. • Koziol D.E.
    • Holland P.V.
    • Alling D.W.
    • et al.
    Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood.
    Ann Intern Med. 1986; 104: 488-495
    View in Article

    • Google Scholar
16. • Levin S.
    • Hahn T.
    Interferon system in acute viral hepatitis.
    Lancet Lond Engl. 1982; 1: 592-594
    View in Article

    • Google Scholar
17. • Hoofnagle J.H.
    • Mullen K.D.
    • Jones D.B.
    • et al.
    Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha Interferon.
    N Engl J Med. 1986; 315: 1575-1578
    View in Article

    • Google Scholar
18. • Der S.D.
    • Zhou A.
    • Williams B.R.G.
    • et al.
    Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays.
    Proc Natl Acad Sci. 1998; 95: 15623-15628
    View in Article

    • Google Scholar
19. • Guo J.T.
    • Sohn J.A.
    • Zhu Q.
    • et al.
    Mechanism of the interferon alpha response against hepatitis C virus replicons.
    Virology. 2004; 325: 71-81
    View in Article

    • Google Scholar
20. • McHutchison J.G.
    • Gordon S.C.
    • Schiff E.R.
    • et al.
    Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    N Engl J Med. 1998; 339: 1485-1492
    View in Article

    • Google Scholar
21. • Reichard O.
    • Andersson J.
    • Schvarcz R.
    • et al.
    Ribavirin treatment for chronic hepatitis C.
    The Lancet. 1991; 337: 1058-1061
    View in Article

    • Google Scholar
22. • Poynard T.
    • Marcellin P.
    • Lee S.S.
    • et al.
    Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
    Lancet Lond Engl. 1998; 352: 1426-1432
    View in Article

    • Google Scholar
23. • Feld J.J.
    • Hoofnagle J.H.
    Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
    Nature. 2005; 436: 967-972
    View in Article

    • Google Scholar
24. • McHutchison J.G.
    • Manns M.
    • Patel K.
    • et al.
    Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.
    Gastroenterology. 2002; 123: 1061-1069
    View in Article

    • Google Scholar
25. • Wills R.J.
    • Dennis S.
    • Spiegel H.E.
    • et al.
    Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection.
    Clin Pharmacol Ther. 1984; 35: 722-727
    View in Article

    • Google Scholar
26. • Tosone G.
    • Borgia G.
    • Gentile I.
    • et al.
    A case of pegylated interferon alpha-related diabetic ketoacidosis: can this complication be avoided?.
    Acta Diabetol. 2007; 44: 167-169
    View in Article

    • Google Scholar
27. • Hegade V.S.
    • Sood R.
    • Saralaya D.
    • et al.
    Pulmonary complications of treatment with pegylated interferon for hepatitis C infection-two case reports.
    Ann Hepatol. 2013; 12: 629-633
    View in Article

    • Google Scholar
28. • Gentile I.
    • Viola C.
    • Reynaud L.
    • et al.
    Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit.
    J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 2005; 25: 283-285
    View in Article

    • Google Scholar
29. • Manns M.
    • Marcellin P.
    • Poordad F.
    • et al.
    Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet Lond Engl. 2014; 384: 414-426
    View in Article

    • Google Scholar
30. • Bacon B.R.
    • Gordon S.C.
    • Lawitz E.
    • et al.
    Boceprevir for previously treated chronic HCV genotype 1 infection.
    N Engl J Med. 2011; 364: 1207-1217
    View in Article

    • Google Scholar
31. • Jacobson I.M.
    • McHutchison J.G.
    • Dusheiko G.
    • et al.
    Telaprevir for previously untreated chronic hepatitis C virus infection.
    N Engl J Med. 2011; 364: 2405-2416
    View in Article

    • Google Scholar
32. • Ezat A.A.
    • Elshemey W.M.
    A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
    Life Sci. 2019; 217: 176-184
    View in Article

    • Google Scholar
33. • Jacobson I.M.
    • Dore G.J.
    • Foster G.R.
    • et al.
    Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Lond Engl. 2014; 384: 403-413
    View in Article

    • Google Scholar
34. • Vaidya A.
    • Perry C.M.
    Simeprevir: first global approval.
    Drugs. 2013; 73: 2093-2106
    View in Article

    • Google Scholar
35. • Reddy K.R.
    • Zeuzem S.
    • Zoulim F.
    • et al.
    Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    Lancet Infect Dis. 2015; 15: 27-35
    View in Article

    • Google Scholar
36. • Lawitz E.
    • Sulkowski M.S.
    • Ghalib R.
    • et al.
    Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
    Lancet Lond Engl. 2014; 384: 1756-1765
    View in Article

    • Google Scholar
37. • Soriano V.
    • Vispo E.
    • de Mendoza C.
    • et al.
    Hepatitis C therapy with HCV NS5B polymerase inhibitors.
    Expert Opin Pharmacother. 2013; 14: 1161-1170
    View in Article

    • Google Scholar
38. • Bhatia H.K.
    • Singh H.
    • Grewal N.
    • et al.
    Sofosbuvir: A novel treatment option for chronic hepatitis C infection.
    J Pharmacol Pharmacother. 2014; 5: 278-284
    View in Article

    • Google Scholar
39. • Abraham G.M.
    • Spooner L.M.
    Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.
    Clin Infect Dis Off Publ Infect Dis Soc Am. 2014; 59: 411-415
    View in Article

    • Google Scholar
40. • Gao M.
    • Nettles R.E.
    • Belema M.
    • et al.
    Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
    Nature. 2010; 465: 96-100
    View in Article

    • Google Scholar
41. • Gitto S.
    • Gamal N.
    • Andreone P.
    NS5A inhibitors for the treatment of hepatitis C infection.
    J Viral Hepat. 2017; 24: 180-186
    View in Article

    • Google Scholar
42. • Pawlotsky J.M.
    NS5A inhibitors in the treatment of hepatitis C.
    J Hepatol. 2013; 59: 375-382
    View in Article

    • Google Scholar
43. • Lee C.
    Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
    Arch Pharm Res. 2011; 34: 1403-1407
    View in Article

    • Google Scholar
44. • Nelson D.R.
    • Cooper J.N.
    • Lalezari J.P.
    • et al.
    All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.
    Hepatol Baltim Md. 2015; 61: 1127-1135
    View in Article

    • Google Scholar
45. • Gane E.J.
    • Pianko S.
    • Roberts S.K.
    • et al.
    Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without Cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
    Lancet Gastroenterol Hepatol. 2017; 2: 805-813
    View in Article

    • Google Scholar
46. • Rodríguez-Torres M.
    Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
    Expert Rev Anti Infect Ther. 2013; 11: 1269-1279
    View in Article

    • Google Scholar
47. • Hézode C.
    Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.
    J Viral Hepat. 2017; 24: 92-101
    View in Article

    • Google Scholar
48. • Feld J.J.
    • Jacobson I.M.
    • Hézode C.
    • et al.
    Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
    N Engl J Med. 2015; 373: 2599-2607
    View in Article

    • Google Scholar
49. • Puoti M.
    • Foster G.R.
    • Wang S.
    • et al.
    High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without Cirrhosis.
    J Hepatol. 2018; 69: 293-300
    View in Article

    • Google Scholar
50. • Manns M.P.
    • Maasoumy B.
    Breakthroughs in hepatitis C research: from discovery to cure.
    Nat Rev Gastroenterol Hepatol. 2022; 19: 533-550
    View in Article

    • Google Scholar
51. • Rincon D.
    • Ripoll C.
    • Iacono O.L.
    • et al.
    Antiviral Therapy Decreases Hepatic Venous Pressure Gradient in Patients with Chronic Hepatitis C and Advanced Fibrosis.
    Off J Am Coll Gastroenterol ACG. 2006; 101: 2269-2274
    View in Article

    • Google Scholar
52. • Curry M.P.
    • O'Leary J.G.
    • Bzowej N.
    • et al.
    Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
    N Engl J Med. 2015; 373: 2618-2628
    View in Article

    • Google Scholar
53. • Charlton M.
    • Everson G.T.
    • Flamm S.L.
    • et al.
    Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Gastroenterology. 2015; 149: 649-659
    View in Article

    • Google Scholar
54. • Manns M.
    • Samuel D.
    • Gane E.J.
    • et al.
    Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Lancet Infect Dis. 2016; 16: 685-697
    View in Article

    • Google Scholar
55. • Pawlotsky J.M.
    • Negro F.
    • Aghemo A.
    • et al.
    EASL recommendations on treatment of hepatitis C: Final update of the series.
    J Hepatol. 2020; 73: 1170-1218
    View in Article

    • Google Scholar
56. • Navasa M.
    • Forns X.
    Antiviral therapy in HCV decompensated Cirrhosis: to treat or not to treat?.
    J Hepatol. 2007; 46: 185-188
    View in Article

    • Google Scholar
57. • Bruchfeld A.
    HCV eradication in chronic kidney disease: ready for prime time?.
    Lancet Gastroenterol Hepatol. 2020; 5: 880-882
    View in Article

    • Google Scholar
58. • Gane E.
    • Lawitz E.
    • Pugatch D.
    • et al.
    Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.
    N Engl J Med. 2017; 377: 1448-1455
    View in Article

    • Google Scholar
59. • Borgia S.M.
    • Dearden J.
    • Yoshida E.M.
    • et al.
    Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
    J Hepatol. 2019; 71: 660-665
    View in Article

    • Google Scholar
60. • Dietz J.
    • Müllhaupt B.
    • Buggisch P.
    • et al.
    Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
    J Hepatol. 2022; S0168-8278: 03016-03021
    View in Article

    • Google Scholar
61. • Semmler G.
    • Meyer E.L.
    • Kozbial K.
    • et al.
    HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2022; 76: 812-821
    View in Article

    • Google Scholar
62. • Abdelrahman T.
    • Hughes J.
    • Main J.
    • et al.
    Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment.
    Hepatol Baltim Md. 2015; 61: 88-97
    View in Article

    • Google Scholar
63. • Dietz J.
    • Susser S.
    • Vermehren J.
    • et al.
    Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Gastroenterology. 2018; 154 (e4): 976-988
    View in Article

    • Google Scholar
64. • Bourlière M.
    • Gordon S.C.
    • Flamm S.L.
    • et al.
    Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
    N Engl J Med. 2017; 376: 2134-2146
    View in Article

    • Google Scholar
65. • Reau N.
    • Kwo P.Y.
    • Rhee S.
    • et al.
    Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
    Hepatol Baltim Md. 2018; 68: 1298-1307
    View in Article

    • Google Scholar
66. • De Mitri M.S.
    • Poussin K.
    • Baccarini P.
    • et al.
    HCV-associated liver cancer without Cirrhosis.
    Lancet Lond Engl. 1995; 345: 413-415
    View in Article

    • Google Scholar
67. • D'Ambrosio R.
    • Degasperi E.
    • Anolli M.P.
    • et al.
    Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    J Hepatol. 2022; 76: 302-310
    View in Article

    • Google Scholar
68. • Piscaglia F.
    • Granito A.
    • Bolondi L.
    DAAs for HCV and risk of hepatocellular carcinoma: current standpoint.
    Lancet Gastroenterol Hepatol. 2018; 3: 736-738
    View in Article

    • Google Scholar
69. • Sanduzzi-Zamparelli M.
    • Mariño Z.
    • Lens S.
    • et al.
    Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
    J Hepatol. 2022; 76: 874-882
    View in Article

    • Google Scholar
70. • Mueller P.P.
    • Chen Q.
    • Ayer T.
    • et al.
    Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    J Hepatol. 2022; 77: 55-62
    View in Article

    • Google Scholar
71. • Ward J.W.
    The Nobel Prize for discovery of HCV is a call to end hepatitis.
    Lancet Lond Engl. 2020; 396: 1733
    View in Article

    • Google Scholar
72. • World Health Organization
    Combating hepatitis B and C to reach elimination by 2030: advocacy brief.
    World Health Organization, 2016 (Available at:)
    https://apps.who.int/iris/handle/10665/206453
    (Accessed November 17, 2022)
    View in Article

    • Google Scholar
73. • Polaris Observatory HCV Collaborators
    Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
    Lancet Gastroenterol Hepatol. 2022; 7: 396-415
    View in Article

    • Google Scholar
74. • Wiktor S.
    How feasible is the global elimination of HCV infection?.
    Lancet Lond Engl. 2019; 393: 1265-1267
    View in Article

    • Google Scholar
75. • Marshall A.D.
    • Matthews G.V.
    Simplifying hepatitis C care models: a crucial step towards hepatitis C elimination.
    Lancet Gastroenterol Hepatol. 2022; 7: 1066-1068
    View in Article

    • Google Scholar
76. • The Lancet Gastroenterology Hepatology null
    Drug pricing: still a barrier to elimination of HCV.
    Lancet Gastroenterol Hepatol. 2018; 3: 813
    View in Article

    • Google Scholar
77. • Buti M.
    • Craxi A.
    • Foster G.R.
    • et al.
    Viral hepatitis elimination: Towards a hepatitis-free world.
    J Hepatol. 2022; 77: 1444-1447
    View in Article

    • Google Scholar
78. • Neumann-Haefelin C.
    • Thimme R.
    Another important step toward a prophylactic vaccine against hepatitis C.
    Hepatol Baltim Md. 2022; 76: 917-919
    View in Article

    • Google Scholar
79. • El Sahly H.M.
    • Baden L.R.
    • Essink B.
    • et al.
    Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
    N Engl J Med. 2021; 385: 1774-1785
    View in Article

    • Google Scholar
80. • Donnison T.
    • McGregor J.
    • Chinnakannan S.
    • et al.
    A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice.
    Hepatol Baltim Md. 2022; 76: 1190-1202
    View in Article

    • Google Scholar